To the Editor: Clavel and Hance (March 4 issue)1 review resistanceto drugs used for the treatment of human immunodeficiency virusinfection. Few data are available concerning patterns of antiretroviral-drugresistance among patients in developing countries. However,the fact that the expected virologic success rates of commonlyused regimens containing nucleoside reverse-transcriptase inhibitorsis approximately 65 percent at 48 weeks is cause for alarm.2
Access to second-line regimens is restricted by their cost,which is currently 10 to 20 times that of first-line regimens.For example, the second-line regimen of tenofovir, didanosine,and either ritonavir or lopinavir, recommended by the . . . [Full Text of this Article]
This article has been cited by other articles:
Larru, B., Resino, S., Bellon, J. M., de Jose, M. I., Fortuny, C., Navarro, M. L., Gurbindo, M. D., Ramos, J. T., Soler Palacin, P., Leon, J. A., Asensi, M., Mellado, M. J., Munoz-Fernandez, M. A.
(2008). Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children. J Antimicrob Chemother
61: 183-190
[Abstract][Full Text]
Drosten, C., Panning, M., Drexler, J. F., Hansel, F., Pedroso, C., Yeats, J., de Souza Luna, L. K., Samuel, M., Liedigk, B., Lippert, U., Sturmer, M., Doerr, H. W., Brites, C., Preiser, W.
(2006). Ultrasensitive Monitoring of HIV-1 Viral Load by a Low-Cost Real-Time Reverse Transcription-PCR Assay with Internal Control for the 5' Long Terminal Repeat Domain. Clin. Chem.
52: 1258-1266
[Abstract][Full Text]
Previous
